

Ref. 3

Section 30-1 (an exception to the lack of novelty) is applied. The invention was published in Vaccine, 12(13); 1241-5 (1994).

#### Claim

1. An intranasal vaccine comprising a liposome, wherein a membrane surface of the liposome binds to an antigen via a lipid for binding the antigen.

[0011]

(d) Others

In addition, examples of other components to be used as the membrane components of the liposome of the present invention include non-ionic surfactants (such as polysorbate), anti-oxidants (such as  $\alpha$ -tocopherol), glycolipids which bind to a mannose (such as 4-o-(6-o-eicosanoyl-b-D-mannopyranosyl)-D-mannopyranose, N-(2-N-cholesterylcarboxymethyl)carbamethylmannan) and the like.

Ref. 5

#### Claim

1. A liposome preparation consisting of a drug, a phospholipid and a fatty acid salt.

[0017]

In general, the liposome obtainable according to the invention is used as injectable solutions. It may be further processed to prepare oral preparations, nasal preparations, ophthalmic preparations, transdermal preparations, suppositories and inhalant preparations.